Role of MRP2 in Chemoresistance in Oesophageal Cancer
Author Information
Author(s): Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M, Doki Y
Primary Institution: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University
Hypothesis
The study investigates the role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcomes in oesophageal squamous cell carcinoma (ESCC).
Conclusion
MRP2 expression is associated with poorer prognosis and chemoresistance in advanced ESCC patients.
Supporting Evidence
- MRP2-positive patients showed poorer prognosis than MRP2-negative patients with a 5-year survival rate of 25.6% vs 55.7%.
- MRP2 expression was significantly higher in ESCC patients who received neo-adjuvant chemotherapy compared to those who did not.
- Non-responders to chemotherapy had 2.9-fold higher MRP2 mRNA expression than responders.
Takeaway
This study found that a protein called MRP2 can make oesophageal cancer harder to treat with chemotherapy, leading to worse outcomes for patients.
Methodology
The study evaluated MRP2 expression using immunohistochemistry and RT-PCR on resected specimens and biopsy samples from ESCC patients.
Limitations
The study could not compare MRP2 expression levels in cancer tissues from the same patient before and after neo-adjuvant chemotherapy due to lack of available samples.
Participant Demographics
The cohort comprised 9 female and 72 male patients, aged from 42 to 80 years (median 62 years).
Statistical Information
P-Value
P=0.0035
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website